Targeted Strategies for Today's Evolving Markets

MissionIR Blog

SteadyMed (STDY) Presents at Rodman & Renshaw Conference

SteadyMed Ltd. (NASDAQ: STDY) is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parental delivery needs. The company’s lead drug product candidate, Trevyent®, utilizes its proprietary PatchPump drug administration platform and is currently being developed to treat pulmonary arterial hypertension. In June 2015, SteadyMed signed an exclusive license and supply agreement for the commercialization of Trevyent in a collection of viable markets – including Europe, Canada and the Middle East. For more information, visit the company’s website at

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. For more information on Rodman & Renshaw, visit
This entry was posted in Rodman and Renshaw Conference. Bookmark the permalink.

Comments are closed.